Market closed
Cara Therapeutics/$CARA
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Cara Therapeutics
Cara Therapeutics Inc is a development-stage biotechnology company involved in the development of novel therapeutics to treat human diseases associated with inflammation, pain, and pruritus. Cara's most advanced compound, CR845, aims to treat acute pain and pruritus. This patented compound has analgesic, anti-inflammatory, and antipruritic properties that can be used for multiple therapeutic applications. Additionally, Cara's objective is to use its proprietary drug-screening technology to develop a future pipeline of first-in-class molecules with analgesic and anti-inflammatory features.
Ticker
$CARA
Sector
Trading on
Industry
Pharmaceuticals
Headquarters
Employees
55
Website
CARA Metrics
BasicAdvanced
$22M
-
-$20.99
0.51
-
Price and volume
Market cap
$22M
Beta
0.51
52-week high
$6.36
52-week low
$4.15
Average daily volume
18K
Financial strength
Current ratio
4.773
Quick ratio
4.324
Long term debt to equity
5,740.17
Total debt to equity
6,223.479
Interest coverage (TTM)
-12.76%
Management effectiveness
Return on assets (TTM)
-61.79%
Return on equity (TTM)
-221.25%
Valuation
Price to revenue (TTM)
2.575
Price to book
31.74
Price to tangible book (TTM)
31.74
Price to free cash flow (TTM)
-0.289
Growth
Revenue change (TTM)
-59.08%
Earnings per share change (TTM)
-18.99%
3-year revenue growth (CAGR)
-59.86%
3-year earnings per share growth (CAGR)
54.03%
CARA News
AllArticlesVideos
CARA THERAPEUTICS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Merger of Cara Therapeutics, Inc. - CARA
Business Wire·3 weeks ago
CARA THERAPEUTICS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Merger of Cara Therapeutics, Inc. - CARA
Business Wire·2 months ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
FAQs
What’s the current market cap for Cara Therapeutics stock?
Cara Therapeutics (CARA) has a market cap of $22M as of March 12, 2025.
What is the P/E ratio for Cara Therapeutics stock?
The price to earnings (P/E) ratio for Cara Therapeutics (CARA) stock is 0 as of March 12, 2025.
Does Cara Therapeutics stock pay dividends?
No, Cara Therapeutics (CARA) stock does not pay dividends to its shareholders as of March 12, 2025.
When is the next Cara Therapeutics dividend payment date?
Cara Therapeutics (CARA) stock does not pay dividends to its shareholders.
What is the beta indicator for Cara Therapeutics?
Cara Therapeutics (CARA) has a beta rating of 0.51. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.